Pharmaceutical Business review

Hospira reports 153% surge in Q1 net income

For the first quarter of 2009, Hospira reported diluted earnings per share of $1.03, an increase of 151.2%, compared to $0.41 for the first quarter of 2008.

The company reported net sales of $859.7 million for the first quarter of 2009, a decrease of 3.3%, compared to $888.7 million for the same period of 2008.

Christopher Begley, chairman and CEO of Hospira, said: “Hospira delivered on its commitments in the first quarter, generating solid sales and earnings growth in a period marked by continued economic uncertainty. Looking forward, we believe the results of our strategic investments and our focus on execution position us well to deliver our financial commitments for 2009.

“In addition, we are driving operational excellence through our optimization initiatives under Project Fuel, which will create long-term, sustainable growth and increased shareholder value.”